Startup Deep Dive : OncoStem Diagnostics — a cheaper breast cancer test that skips chemo yet reaches under 10% of eligible women

Dr Manjiri Bakre has spent fifteen years building a laboratory test that can spare roughly half of early-stage breast cancer patients from chemotherapy they do not need. Yet after raising about $9 million (roughly ₹86 crore at $1 ≈ ₹96.0, 18 September 2026) in venture funding, her Bengaluru company, OncoStem Diagnostics, turned over only ₹7.15 crore ($0.74 million) in the year to March 2024, and describes itself today as merely “operationally break-even”.

That gap between clinical promise and commercial scale is the whole story of OncoStem. India diagnoses around 200,000 new breast cancer patients a year; by the company’s own reckoning, 50,000 to 60,000 of them could benefit from a recurrence-risk test, and only 6,000 to 7,000 actually get one. OncoStem built a homegrown test that costs a fraction of imported rivals, published its validation in peer-reviewed journals, and still cannot reach most of the patients it was designed for. In September 2026 the company said it wants to fix that by turning its test from a service into a kit. This is how a deep-science startup gets stuck in the last mile, and what it is trying now.

Quick facts

What OncoStem actually does

OncoStem sells a prognostic decision, not a drug. Its flagship product, CanAssist Breast, is a test that tells an oncologist how likely a specific patient’s early-stage breast cancer is to come back within five years, so the doctor and patient can decide whether chemotherapy is worth its harm. It is aimed at a defined group, and it works in a specific way:

• Who it is for: patients with early-stage (Stage 1 to 3A), hormone-receptor-positive, HER2-negative breast cancer, per the company’s clinical description.
• What it measures: a proprietary combination of protein biomarkers read from the patient’s tumour tissue by immunohistochemistry, combined with clinical parameters, run through a proprietary machine-learning algorithm to output a five-year recurrence risk score classifying the patient as low-risk or high-risk (OncoStem).
• What it changes: the company says close to 50% of patients can avoid the side-effects of unnecessary chemotherapy, and reports that around 70% of patients tested through CanAssist Breast avoided chemotherapy (OncoStem, via Business Standard, September 2026).
• Validation: the test was validated in a retrospective multi-centric study across 15-plus centres in India, the USA and Europe on close to 2,000 patients, with results published in peer-reviewed journals including Biomarker Insights and Cancer Medicine (OncoStem).
• Accreditation and reach: the reference laboratory holds College of American Pathologists (CAP) and NABL accreditation; the test has been offered in India and neighbouring markets including Sri Lanka and Bangladesh (OncoStem; Inc42).

The origin: a friend, a PhD and a gap in Indian oncology

The idea began with a death, not a business plan. Dr Manjiri Bakre earned a PhD in cell biology from the Indian Institute of Science, Bangalore, in 1998. She has said that one of the triggers for OncoStem was losing a good friend to breast cancer during those PhD years, an experience that pointed her toward the question the company still answers: which patients actually need aggressive treatment, and which are being over-treated.

Her route to founding was not straight. After two post-doctoral fellowships in the United States, Bakre returned to India around 2007 and led a group in cancer drug discovery at Avesthagen, then worked on point-of-care diagnostics at Philips Research in Bangalore and the Netherlands. That combination mattered. She had bench-level cancer biology, industrial diagnostics experience, and a clear clinical problem. In India, oncologists prescribing chemotherapy for early-stage breast cancer were largely doing so without a recurrence-risk test tuned to Indian patients, while imported genomic assays cost several lakh rupees and were priced out of reach for most. Bakre incorporated Oncostem Diagnostics Private Limited on 15 March 2011 to close that gap with a test built and validated in India, at Indian prices.

The struggle years: building deep science on a thin runway

Deep-tech diagnostics is a slow, capital-hungry business, and OncoStem’s timeline shows it. The company was incorporated in 2011, but its product had to be discovered, validated across multiple centres and published before a single oncologist would trust it with a treatment decision. That is years of spending before meaningful revenue, and the filings and reporting show a company that stayed small and lean rather than scaling fast.

Two hard realities defined this stretch. First, adoption is a clinician-by-clinician grind: a prognostic test only sells when oncologists build it into their treatment protocols, and that trust is earned through published evidence, not marketing. OncoStem’s validation on close to 2,000 patients across 15-plus centres, published in international journals, was the price of entry, not a growth lever. Second, the money had to last. The company raised roughly $9 million across its life and, even in September 2026, said it had a funding runway of only one to two years, which is the profile of a firm that has husbanded a modest amount of capital over more than a decade rather than one that raised big and spent fast.

The financials carry the scars. Revenue did not climb in a clean line. Company records show OncoStem’s revenue fell about 43.7% year-on-year in FY23 (year ended 31 March 2023), and net profit swung sharply negative that year, a decline reported at more than 2,000% versus the prior year, with net worth down about 41% (RoC filings via CompanyCheck/Tofler). For a company fifteen years old, staying at single-digit-crore revenue and only reaching “operationally break-even” is the unsoftened truth: the science worked long before the business did.

The turning point: from clinical proof to the kit decision

OncoStem’s turning point is not a fundraise or an acquisition. It is a decision, announced in September 2026, to change how the test is delivered, because the old model had hit a wall that no amount of clinical validation could break through.

The numbers on each side of that wall are stark. India diagnoses roughly 200,000 new breast cancer patients a year, of whom the company estimates 50,000 to 60,000 could be eligible for prognostic testing. Yet only about 6,000 to 7,000 patients a year actually undergo CanAssist Breast or an imported test, and OncoStem’s own annual volume runs at roughly 3,000 tests. The reason is structural: CanAssist Breast has been performed as a service at OncoStem’s single Bengaluru reference laboratory, which means every tumour sample has to travel to one lab, adding cost, delay and friction for hospitals across the country.

The fix is to decentralise. In September 2026 Bakre told Business Standard the company is converting CanAssist Breast into a kit that hospital pathology laboratories can run in-house, rather than shipping samples to Bengaluru. She said the company aims to at least double its annual testing volume to around 6,000 tests, that the kit could enter the market in six to eight months subject to evaluation, hospital ethics-committee approvals and final regulatory clearance, and that OncoStem does not need additional capital for the initial production of the kits. If it works, the same test reaches many more patients without the logistics of a central lab. That is the bet the company is now making.

The money behind it

OncoStem is a modestly funded, patient-capital story rather than a mega-round one. The shape of its funding, as reported by Inc42, Entrackr, YourStory and Business Standard:

• First backing (2011): California-based Artiman Ventures provided the company’s earliest funding, reported at about $3 million (roughly ₹29 crore) invested in multiple tranches (Entrackr/YourStory, September 2017).
• Sequoia round (September 2017): OncoStem raised $6 million (roughly ₹58 crore) led by Sequoia Capital India (now Peak XV Partners), with existing investor Artiman Ventures participating. The round was reported independently by Inc42, Entrackr, BW Businessworld, YourStory and IBEF.
• Total raised: about $9 million (roughly ₹86 crore) across its life, per multiple sources.
• What the money changed: Sequoia’s 2017 capital was earmarked to deepen R&D, extend the pipeline to tests for oral, brain and colon cancer, automate the tests and expand geographically (Inc42, September 2017).
• Valuation: not publicly disclosed in any of the sources reviewed; OncoStem remains a private, unlisted company.

Two things stand out. The company has not announced a large new round in the years since 2017, and by September 2026 it was operating on a one-to-two-year runway, funding its kit transition from existing resources rather than fresh capital. For a deep-science diagnostics firm, that is a deliberately frugal posture.

How OncoStem makes money

The economics are those of a specialist reference laboratory, and the September 2026 kit plan is an attempt to change them. Here is the model as the public record describes it:

• Money in (today): revenue per test performed at the Bengaluru reference lab. The laboratory-based test is priced at around ₹60,000, per Business Standard (September 2026).
• The price advantage: that ₹60,000 sits well below imported genomic alternatives; Oncotype DX is reported to cost roughly ₹2.5 lakh to ₹3.6 lakh in India, based on prices listed by Indian healthcare providers and distributors (Business Standard, September 2026). Affordability is OncoStem’s central commercial argument.
• Where the margin sits: as a lab-service model, OncoStem carries the fixed cost of running an accredited central laboratory against a low volume of roughly 3,000 tests a year, which is why the company reached only “operationally break-even” rather than strong profitability.
• The kit model (planned): converting to a kit that hospital labs run in-house shifts OncoStem toward selling kits and know-how rather than performing every test itself, which can lift volume without the central-lab logistics, though typically at a different per-test economics.
• The part people get wrong: a cheaper test does not automatically mean a bigger business. OncoStem’s low price widens access but also caps revenue per patient, so scale depends on volume, and volume was exactly what the single-lab model constrained.

The numbers

OncoStem’s public financials are those of a small, still-scaling company, and they are volatile year to year. The one firm audited-filing figure is FY24 revenue; the year-on-year movements around it come from the same RoC-based sources. All figures below are in ₹ crore.

The honest reading: FY23 was a bad year, with revenue and profit both falling sharply, and FY24 was a rebound to ₹7.15 crore with profit back in positive territory. The FY25 figure is a data-provider estimate, not an audited number, and should be treated as such. What is not in dispute is scale: even after the FY24 recovery, this is a single-digit-crore business, which is why the company frames itself as break-even rather than profitable-at-scale.

Where the money comes from

OncoStem’s revenue base is narrow by product and by geography, which is both its focus and its constraint:

• By product: revenue is concentrated in one test, CanAssist Breast, for early-stage HR-positive, HER2-negative breast cancer. The company has spoken of a pipeline extending to oral, brain and colon cancer tests since its 2017 fundraise, but breast cancer recurrence remains the commercial core (Inc42; OncoStem).
• By geography: India is the primary market, with the test also offered in neighbouring countries including Sri Lanka and Bangladesh (Inc42).
• By channel: historically a single Bengaluru reference laboratory processing samples referred by oncologists and hospitals nationwide; the September 2026 kit plan is designed to add hospital-lab channels.
• The surprise: the addressable market is far larger than the served market. Against an estimated 50,000 to 60,000 eligible patients a year in India, only 6,000 to 7,000 are tested at all, and OncoStem does around 3,000 of those, meaning the company serves well under 10% of the patients its own product is built for (company estimates via Business Standard, September 2026).

The risks

The risks facing OncoStem are concrete and, in several cases, disclosed or implied by the company’s own statements:

• Runway and single-product concentration: the company said in September 2026 it has a funding runway of one to two years and depends heavily on one test. A stumble in the kit launch, or a slower-than-hoped volume ramp, would pressure a business that is only operationally break-even, with FY24 revenue of ₹7.15 crore (Business Standard; RoC filings).
• Regulatory and adoption execution: the kit’s arrival is explicitly conditional on evaluation, hospital ethics-committee approvals and final regulatory clearance, and Bakre put the timeline at six to eight months. Each of those is a gate that can slip, and decentralising a test to many hospital labs also raises quality-control and standardisation questions that a single accredited lab does not face (Business Standard, September 2026).
• Adoption and reimbursement ceiling: even at around ₹60,000, versus roughly ₹2.5-3.6 lakh for imported Oncotype DX, the test reaches only a small share of eligible patients. In a largely out-of-pocket market with limited insurance reimbursement for prognostic testing, a low price has not been enough to unlock volume, which is the core commercial risk the kit strategy is meant to address (Business Standard, September 2026).

The takeaway

OncoStem is a reminder that in health-tech, being right about the science is the easy part. Dr Bakre’s team proved, in peer-reviewed journals and across thousands of patients, that a homegrown test could spare many Indian women from chemotherapy they did not need, and priced it at a fraction of imported rivals. None of that was enough to make the company big. Fifteen years and about $9 million in, OncoStem turned over ₹7.15 crore in FY24 and calls itself break-even, because the bottleneck was never the test’s accuracy. It was distribution, price sensitivity and the sheer friction of routing every sample to one lab. The transferable lesson is blunt: for a diagnostics or deep-tech company, the delivery model is as much a part of the product as the technology, and a brilliant test locked inside a single laboratory reaches only the patients who can get to that laboratory. OncoStem’s kit gamble is, in the end, an admission that the next decade of the company depends less on the biology it has already solved than on the logistics it has not.

Frequently asked questions

What does OncoStem Diagnostics do?

OncoStem is a Bengaluru cancer-diagnostics company founded in 2011 by Dr Manjiri Bakre. Its flagship product, CanAssist Breast, is a prognostic test that estimates the five-year recurrence risk of early-stage, HR-positive, HER2-negative breast cancer, helping oncologists decide whether a patient needs chemotherapy.

How much has OncoStem raised and from whom?

OncoStem has raised about $9 million (roughly ₹86 crore) in total. Its earliest backing came from Artiman Ventures around 2011 (reported at about $3 million in tranches), and in September 2017 it raised $6 million led by Sequoia Capital India, now Peak XV Partners, with Artiman participating. No valuation has been publicly disclosed.

How much money does OncoStem make?

Per Registrar of Companies filings accessed via CompanyCheck and Tofler, OncoStem reported operating revenue of ₹7.15 crore in FY24 (year ended 31 March 2024), a rebound of about 40% after a weak FY23. As of September 2026 the company described itself as operationally break-even.

How much does the CanAssist Breast test cost?

The laboratory-based test is priced at around ₹60,000, according to Business Standard (September 2026). That is well below imported genomic tests such as Oncotype DX, reported at roughly ₹2.5 lakh to ₹3.6 lakh in India.

What is OncoStem’s plan to grow?

In September 2026 OncoStem said it is converting CanAssist Breast from a central-lab service into a kit that hospital pathology labs can run in-house, aiming to at least double annual testing volume to around 6,000 tests. The kit could reach the market in six to eight months, subject to evaluation, ethics-committee approvals and regulatory clearance.

Sources

Figures are as of September 2026. Currency converted at $1 ≈ ₹96.0 as of 18 September 2026 (Trading Economics).

• Business Standard — “OncoStem eyes wider access to breast cancer risk test with hospital-use kit” (September 2026): test price, break-even status, runway, addressable-market and volume figures, kit timeline, chemotherapy-avoidance rate, Oncotype DX price comparison.
• Inc42 — “Sequoia India Leads $6 Mn Funding Round In Oncology, Cancer Diagnostics Startup OncoStem” (September 2017): funding, founding year, technology, pipeline, geographic reach.
• Entrackr — “OncoStem Diagnostics secures $6 Mn from Sequoia Capital” (September 2017): 2017 round and earlier Artiman funding of about $3 million in tranches.
• YourStory — “OncoStem Diagnostics raises $6 million” (September 2017) and company profile: total raised, investors, founder background.
• BW Businessworld / IBEF (September 2017): independent confirmation of the $6 million Sequoia-led round.
• CompanyCheck and Tofler — Oncostem Diagnostics Private Limited financials (RoC/MCA filings, CIN U85110KA2011PTC057624): FY24 revenue ₹7.15 crore, FY23 and FY24 year-on-year movements, incorporation date, capital, directors.
• OncoStem Diagnostics — company website (about, CanAssist Breast pages): test description, technology, validation study, CAP/NABL accreditation.
• Entrepreneur India / IHW Council / indiaai.gov.in — founder biography and career history for Dr Manjiri Bakre.

Found an error? Write to us and we’ll correct it in the open, dated, on the piece.